Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, both of which promote osteogenic differentiation in human periosteum-derived cells (hPDC). Consequently, Bimekizumab inhibits inflammation-driven osteogenic differentiation [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, both of which promote osteogenic differentiation in human periosteum-derived cells (hPDC). Consequently, Bimekizumab inhibits inflammation-driven osteogenic differentiation [1]. |
Molecular Weight | N/A |
CAS No. | 1418205-77-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bimekizumab 1418205-77-2 inhibitor inhibit